From the Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel.
J Biol Chem. 2010 Jul 2;285(27):20423-7. doi: 10.1074/jbc.R110.134452. Epub 2010 Apr 29.
Lysosomal storage diseases (LSDs), of which about 50 are known, are caused by the defective activity of lysosomal proteins, resulting in accumulation of unmetabolized substrates. As a result, a variety of pathogenic cascades are activated such as altered calcium homeostasis, oxidative stress, inflammation, altered lipid trafficking, autophagy, endoplasmic reticulum stress, and autoimmune responses. Some of these pathways are common to many LSDs, whereas others are only altered in a subset of LSDs. We now review how these cascades impact upon LSD pathology and suggest how intervention in the pathways may lead to novel therapeutic approaches.
溶酶体贮积症(LSDs)已知约有 50 种,是由溶酶体蛋白活性缺陷引起的,导致未代谢的底物积累。结果,多种致病级联反应被激活,如钙稳态改变、氧化应激、炎症、脂质转运改变、自噬、内质网应激和自身免疫反应。这些途径中的一些在许多 LSD 中是共同的,而另一些则仅在 LSD 的亚组中改变。我们现在回顾这些级联反应如何影响 LSD 病理学,并提出干预这些途径可能导致新的治疗方法。